Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

SOMERSET, N.J., June 19 /PRNewswire-FirstCall/ --

Dear Shareholder,

I am grateful to have this opportunity to share with you important developments taking place at this critical juncture in our company history. This communication shall mark what I hope will be the first of many as your president.

Like many of you, I also have been a longtime shareholder and supporter of this company. I want you to know I am fully committed no matter how difficult the challenge, to see this company and our valuable compounds realize their full potential.

As you are aware, we did not meet our primary endpoint of overall survival in our Phase IIIb clinical trial in patients suffering from unresectable malignant mesothelioma (UMM). We did however; achieve statistical significance with a subgroup of patients who failed a prior chemo therapy. Overall survival was 10.5 months for this group. As we reported in January 2009, we had a pre-NDA meeting with the FDA and the FDA provided guidance to the company recommending that an additional trial be conducted in UMM patients that have failed at least one prior chemotherapy regimen prior to submitting an NDA. Considering Onconase's overall safety profile, its ability to overcome MDR, I believe that Onconase remains a viable candidate for second line therapy in MM.

The fact that Onconase was able to extend the lives of patients who had failed a prior chemo therapy was not lost in our thoughts. About a year ago, we engaged Champions Biotechnology, to conduct a series of animal studies on immune deficient mice to see what effect Onconase would have on human tumors grafted onto these mice. Tumorgrafts parallel sensitivity and resistance in the clinic. The results showed Onconase has a documented synergistic effect in Cisplatin sensitive and resistant NSCLC. We are not surprised by these results and believe Onconase has the potential to overcome multipl
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... , Part of International Internet Week ... The U.S. Food and Drug Administration today completed ... Week of Action (IIWA), intended to curb illegal actions ... During the effort, the FDA,s Office of Criminal Investigations ...
... , Primary Care Doctors, Endocrinologists Feel ... N.J., Nov. 19 Nearly one-third of doctors surveyed said ... sufficient reimbursement to provide comprehensive care to their patients with ... and primary care doctors published today in American Health ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Delaying surgery to repair damage to ... the middle of the knee -- could increase a young ... the medical records of 130 patients, aged 8 to 16, ... surgery less than six weeks after their injury, 37 had ... surgery more than three months after their injury. The ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... ... tests green product performance on real-world soils. , ... Lowell, MA (PRWEB) April 22, 2010 -- The ... Massachusetts Lowell (UMass Lowell) TURI Lab as a High Performance Cleaning Product (HPCP) under ...
... The New Mexico ... ... Tamaya Mist Spa & Salon at the Hyatt Regency Tamaya Resort & Spa has recently ... the nation,s leading travel magazines. The New Mexico spa resort was ranked as the ...
... Major ... cannabis , ... April 22, 2010 -- MarijuanaDoctors.com, the nation’s leading online medical marijuana evaluations company, and ... forces to help patients across the country find quality medical marijuana doctors ...
... ... coverage – just the beginning. , ... Waterloo, IA (Vocus) April 21, 2010 -- VGM ... including: Home Medical Equipment, Durable Medical Equipment, Orthotic, Prosthetic, Medical Device Manufacturers, Medical ...
... According to a study conducted at Thomas Jefferson ... a cost-effective alternative to invasive cardiac catheterization in the ... but a less than 50 percent chance of actually ... will be published in the May issue of the ...
... before the Medicare Evidence Development and Coverage Advisory ... treatment of localized prostate cancer. MEDCAC provides advice ... Medicaid Services for what is covered by Medicare ... focused on the risks, benefits and outcomes of ...
Cached Medicine News:Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 2Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 3Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 2Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 3Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 2Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 3Health News:Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD 2
... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
... surgical magnifying loupes are quality surgical ... which provide the healthcare professional a ... depth of field. Each set of ... fully lined wooden box and includes ...
... field-of-view enables high-quality full-coverage body imaging. New ... architecture. New powerful Quasar Dual gradients designed ... to 80 mT/m SR 200. New ... exploit the power of 3.0T in a ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Medicine Products: